Companies: 49,246 Total Market Cap: 132441797263938.02

Prothena Corporation plc

NASDAQ: PRTA
Healthcare Biotechnology
Rank #15078
Market Cap 402.63 M
Volume 490,064
Price 7.48
Change (%) 1.08%
Country or region Ireland Ireland

Prothena Corporation plc's latest marketcap:

402.63 M

As of 05/20/2025, Prothena Corporation plc's market capitalization has reached $402.63 M. According to our data, Prothena Corporation plc is the 15078th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.

Market Cap 402.63 M
Revenue (ttm) 137.94 M
Net Income (ttm) -110,266,000
Shares Out 53.83 M
EPS (ttm) -2.05
Forward PE 0.00
Ex-Dividend Date n/a
Earnings Date 05/08/2025
Market Cap Chart
Data Updated: 05/20/2025

Prothena Corporation plc's yearly market capitalization.

Prothena Corporation plc has seen its market value grow from $129.60 M to $402.63 M since 2012, representing a total increase of 210.67% and an annual compound growth rate (CAGR) of 9.58%.
Date Market Cap Change (%)
05/20/2025 $402.63 M -46.34%
12/31/2024 $745.30 M -61.78%
12/29/2023 $1.95 B -33.09%
12/30/2022 $2.91 B 26.63%
12/31/2021 $2.30 B 380.02%
12/31/2020 $479.50 M -24.08%
12/31/2019 $631.60 M 53.82%
12/31/2018 $410.60 M -71.51%
12/29/2017 $1.44 B -15.04%
12/30/2016 $1.70 B -20.98%
12/31/2015 $2.15 B 277.66%
12/31/2014 $568.50 M -1.92%
12/31/2013 $579.60 M 347.22%
12/31/2012 $129.60 M

Company Profile

About Prothena Corporation plc

Prothena Corporation plc is a late-stage clinical biotechnology company specializing in the discovery and development of novel therapies for diseases caused by protein dysregulation. Headquartered in Dublin, Ireland, the company was founded in 2012.

Key Product Pipeline

  • Birtamimab – A humanized antibody in Phase 3 clinical trials for AL amyloidosis.
  • Prasinezumab – A humanized monoclonal antibody in Phase 2b trials for Parkinson’s disease and other synucleinopathies.
  • Coramitug – An investigational antibody in Phase 2 trials for transthyretin amyloidosis.
  • BMS-986446 – An antibody in Phase 2 trials for Alzheimer’s disease.
  • PRX012 – An investigational antibody in Phase 1 trials for Alzheimer’s disease.
  • PRX123 – A Dual Aβ-Tau Vaccine in preclinical trials for Alzheimer’s disease.
  • PRX019 – An investigational antibody in Phase 1 trials for neurodegenerative diseases.

Strategic Collaborations

Prothena has established key partnerships to advance its research:

  • F. Hoffmann-La Roche Ltd. – License, development, and commercialization agreement for α-synuclein-targeting antibodies, including prasinezumab.
  • Bristol Myers Squibb – Master collaboration agreement to develop antibodies targeting tau and TDP-43.
Frequently Asked Questions

As of 05/20/2025, Prothena Corporation plc (including the parent company, if applicable) has an estimated market capitalization of $402.63 M USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.

Prothena Corporation plc global market capitalization ranking is approximately 15078 as of 05/20/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.

Stock Detail

Country or region Ireland
Founded 2012
IPO Date n/a
Employees 163
CEO Gene Kinney
Sector Healthcare
Industry Biotechnology
Address 77 Sir John Rogerson’s Quay, Block C
Dublin, D02 VK60
Ireland
Website https://www.prothena.com
People Also Watch
VRTX
444.31 1.08%
CSL Limited
156.27 1.08%
REGN
605.54 1.08%
KRX-207940
731.22 1.08%